# OnCo record basilea (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/basilea/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "basilea" ;
  schema:name "Basilea Pharmaceutica"@en ;
  schema:alternateName "Basilea Pharmaceutica Ltd"@en, "Basilea"@en ;
  schema:description "Basilea is a Swiss company now focused on anti-infectives that ran phase 3 cancer trials of the FGFR inhibitor derazantinib and the tumour checkpoint controller lisavanbulin before divesting its oncology work in 2022."@en ;
  schema:url <https://onco.cc/companies/basilea/>, <https://www.basilea.com> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Basilea_Pharmaceutica> ;
  owl:sameAs <http://www.wikidata.org/entity/Q810060> ;
  schema:citation <https://www.basilea.com>, <https://clinicaltrials.gov/search?lead=Basilea%20Pharmaceutica>, <https://en.wikipedia.org/wiki/Basilea_Pharmaceutica> ;
  onco:tag "ctgov-sponsor" ;
  schema:addressCountry "CH" ;
  onco:cancers <https://onco.cc/cancers/cholangiocarcinoma/>, <https://onco.cc/cancers/urothelial/>, <https://onco.cc/cancers/glioblastoma/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/fgfr2/> .